Effect of Infliximab in oxidised serum albumin levels during experimental colitis.
Infliximab (IFX) is widely used in ulcerative colitis and in Crohn's disease treatment. Both diseases are characterised by increased oxidative stress, which may affect albumin oxidation. In order to test this hypothesis, the effect of IFX on colitis induced by dextran sulphate sodium (DSS) in rats was evaluated by measuring the Disease Activity Index, biochemical parameters, serum albumin oxidation and colonic mucosa oxidation. Rats with colitis showed an increase in oxidised serum albumin levels and in the oxidation of colon mucous cells. Both decreased after IFX treatment. This suggests that oxidised albumin could be a useful biomarker for monitoring inflammatory bowel disease.
Department of Systems Biology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Alcalá , Alcalá de Henares , Spain .
David
D
Cano-Martínez
Irene D
ID
Román
M Val
MV
T Lobo
Oscar
O
Pastor
Irene
I
Moreno-Villena
Alberto
A
Paradela
Borja
B
Hernández-Breijo
Ma Dolores
MD
Fernández-Moreno
Jorge
J
Monserrat
Patricia
P
Sanmartín-Salinas
Javier P
JP
Gisbert
Luis G
LG
Guijarro
D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D056945:Hep G2 Cells; D006801:Humans; D000069285:Infliximab; D008297:Male; D010084:Oxidation-Reduction; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000911:Antibodies, Monoclonal; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
Biomarker; carbonylated albumin; dextran sulfate sodium; inflammatory bowel disease